Tesamorelin

🔬Kas yra Tesamorelin

Tesamorelin is a synthetic 44-amino acid analog of growth hormone-releasing hormone (GHRH), modified with a trans-3-hexenoic acid group at the N-terminus to improve stability and extend half-life compared to natural GHRH. It is the only FDA-approved GHRH analog (as Egrifta®/Egrifta SV®) specifically indicated for reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy. By selectively stimulating pituitary GH release, Tesamorelin preferentially targets deep visceral fat while preserving subcutaneous fat and lean mass. Extensive randomized controlled trial data demonstrates significant reductions in trunk fat, waist circumference, and improvements in body image without the side effects of direct HGH therapy.

📊Klinikiniai tyrimai ir rezultatai

Tesamorelin is an FDA-approved synthetic GHRH analog specifically validated for visceral fat reduction in clinical trials:

• ▪Phase III RCT demonstrated Tesamorelin reduced visceral adipose tissue (VAT) by a mean of 34 cm² and additionally reduced liver fat in HIV-infected patients with abdominal fat accumulation (Stanley et al., JAMA, 2014; PMID: 25038357)
• ▪FDA-approved in 2010, Tesamorelin is the only GHRH analog specifically indicated for reduction of excess abdominal fat, distinguishing it from other GH secretagogues
• ▪Long-term efficacy data confirmed Tesamorelin maintained visceral fat reduction with sustained improvement in waist circumference over 26-week treatment periods in phase III trials
• ▪Tesamorelin improved triglyceride levels and other metabolic markers associated with visceral adiposity, demonstrating benefits beyond fat reduction alone
• ▪Post-hoc analysis confirmed Tesamorelin is equally effective regardless of fat distribution pattern, including patients with dorsocervical fat accumulation (Cambridge, 2022)

Tesamorelin is the only FDA-approved GHRH analog with specific indication for visceral fat reduction, supported by rigorous phase III clinical trial evidence for both efficacy and safety.

🏆Privalumai

• FDA-approved for visceral fat reduction – Only GHRH analog approved for treating HIV-associated lipodystrophy
• Preferentially targets deep visceral abdominal fat – Reduces the most metabolically dangerous fat depot
• Preserves lean muscle mass – Unlike caloric restriction, does not cause muscle wasting
• Significant waist circumference reduction – Clinical trials show measurable decreases within 26 weeks
• Improves body image and quality of life – Patient-reported outcomes show substantial psychological benefits
• Stimulates natural GH production – Works through the body's own pituitary regulatory system
• May improve cognitive function – Emerging research suggests benefits for memory and executive function in aging

⚠️Galimas šalutinis poveikis

• ▪Injection site reactions (erythema, pruritus, pain, irritation) – most common adverse effect
• ▪Muscle or joint aches and pains
• ▪Peripheral edema (fluid retention) in some subjects
• ▪Nausea and upper abdominal discomfort
• ▪Changes in blood sugar levels – requires monitoring in subjects with diabetes risk
• ▪Elevated IGF-1 levels – periodic monitoring recommended
• ▪Contraindicated in active malignancy and during pregnancy
• ▪Hypersensitivity reactions including rash and urticaria (rare)

🎯Idealiai tinka

• →Visceral fat reduction and body composition research
• →HIV-associated lipodystrophy treatment studies
• →Metabolic syndrome and cardiometabolic risk reduction
• →Growth hormone optimization through GHRH pathway
• →Cognitive function and aging research
• →Comparison studies with Sermorelin and other GH secretagogues